VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,224,611 | -6.8% | 82,868 | -8.7% | 0.01% | 0.0% |
| Q2 2023 | $4,534,202 | +60.8% | 90,793 | +20.7% | 0.01% | +50.0% |
| Q1 2023 | $2,820,407 | -20.4% | 75,251 | +1.8% | 0.00% | -33.3% |
| Q4 2022 | $3,543,313 | +187.4% | 73,896 | +43.8% | 0.01% | +200.0% |
| Q3 2022 | $1,233,000 | +10.6% | 51,377 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $1,115,000 | +27.1% | 51,237 | +41.1% | 0.00% | +100.0% |
| Q1 2022 | $877,000 | -6.6% | 36,314 | -8.0% | 0.00% | 0.0% |
| Q4 2021 | $939,000 | -3.2% | 39,465 | +3.2% | 0.00% | 0.0% |
| Q3 2021 | $970,000 | -21.3% | 38,238 | -30.2% | 0.00% | -50.0% |
| Q2 2021 | $1,233,000 | +42.9% | 54,790 | +25.4% | 0.00% | +100.0% |
| Q1 2021 | $863,000 | +17.9% | 43,698 | +58.6% | 0.00% | 0.0% |
| Q4 2020 | $732,000 | -46.2% | 27,559 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $1,361,000 | – | 27,559 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $99,174,000 | 24.03% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $44,903,000 | 11.24% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,111,485 | $26,442,000 | 11.06% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $54,944,000 | 4.23% |
| Kynam Capital Management, LP | 211,483 | $5,031,000 | 2.69% |
| GREAT POINT PARTNERS LLC | 500,000 | $11,895,000 | 2.64% |
| Ghost Tree Capital, LLC | 250,000 | $5,948,000 | 2.13% |
| RA Capital Management | 4,240,464 | $100,881,000 | 1.78% |
| Opaleye Management Inc. | 315,800 | $7,513,000 | 1.59% |
| Ikarian Capital, LLC | 295,111 | $7,021,000 | 1.05% |